Analysis of the Clinical Effect of Combined Drug Susceptibility to Guide Medication for Carbapenem-Resistant Patients Based on the Kirby-Bauer Disk Diffusion Method

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2021 Jan 20

PMID 33469322

Citations 13

Authors

Huijuan Yao

Jingxian Liu

Xueyan Jiang

Feng Chen

Xiaotong Lu

Jian Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the in-vitro antibacterial activity of drug combinations against carbapenem-resistant (CRKP) and to explore the guiding significance of the combined drug susceptibility results for determining the clinical efficacy in patients with CRKP infection.

Methods: Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method. The clinical data of CRKP-infected patients and the drug susceptibility results of sample cultures were gathered and retrospectively analyzed.

Results: All 16 CRKP patients had underlying diseases, of which the bloodstream infection was the most common one. Intensive care unit admission history, invasive operation history, and poor nutritional status were recorded to be the high-risk factors. The in-vitro drug susceptibility results indicated that CRKP exhibited 100%, 75.0%, and 66.7% susceptibilities to tigecycline, polymyxin, and ceftazidime/avibatan, respectively. In case of two-drug combinations, polymyxin+tigecycline, ceftazidime avibatan+tigecycline or (aztreonam, polymyxin B, fosfomycin), fosfomycin+polymycin, imipenem+tigecycline, and fosfomycin+tigecycline exhibited 100%, 87.5% (81.3%, 75.0%, 75.0%), 68.8%, 68.8%, and 62.5%, respectively, synergistic and/or cumulative antibacterial effects. Three-drug combinations such as imipene+tigecycline+polymyxin, imipenem+fosfomycin+tigecycline, imipenem+fosfomycin+polymyxin, and ceftazidime avibatan+polymyxin+fosfomycin demonstrated 75.0%, 68.8%, 62.5%, and 62.5% synergistic effects, respectively. The clinical efficacy results revealed that the combination of imipenem+tigecycline+fosfomycin showed the best results, followed by meropenem+fosfomycin, imipenem+tigecycline, ceftazidime avibatan, and ceftazidime+amikacin.

Conclusion: The combined drug susceptibility results can facilitate guidance of the adjustment of antibacterial drug treatment regimens in patients with CRKP infection. For controlling the CRKP infection, it was found that treatment with carbapenems or ceftazidime avibatan demonstrated better antibacterial activity when combined with tigecycline and/or fosfomycin and/or polymyxin B.

Citing Articles

Characterizing the bacteriophage PKp-V1 as a potential treatment for ESBL-producing hypervirulent K1 ST258 isolated from veterinary specimens.

Tariq M, Muzammil S, Ashfaq U, Arshad M, Shafique M, Ejaz H Vet World. 2024; 17(9):2008-2016.

PMID: 39507776 PMC: 11536733. DOI: 10.14202/vetworld.2024.2008-2016.

In Vitro Synergistic Effect of Colistin with Fosfomycin Against Carbapenem-Resistant Klebsiella pneumoniae.

P C, A T, Murthy N, Rao M Cureus. 2024; 16(8):e66295.

PMID: 39238681 PMC: 11376468. DOI: 10.7759/cureus.66295.

Characterization of Antibiofilm and Antimicrobial Effects of Stingless Bee Honey Compared to Stinging Bee and Honeys.

Aburayyan W, Seder N, Al-Fawares O, Fararjeh A, Majali I, Al-Hajaya Y J Evid Based Integr Med. 2024; 29:2515690X241271978.

PMID: 39118572 PMC: 11311187. DOI: 10.1177/2515690X241271978.

Essential Oil of Fractionated Oregano as Motility Inhibitor of Bacteria Associated with Urinary Tract Infections.

Sanchez Garcia E, Torres-Alvarez C, Morales Sosa E, Pimentel-Gonzalez M, Villarreal Trevino L, Amaya Guerra C Antibiotics (Basel). 2024; 13(7).

PMID: 39061347 PMC: 11273670. DOI: 10.3390/antibiotics13070665.

pKpQIL-like plasmid contributes to the dissemination of and plasmid mediated quinolone resistance determinants among multi drug resistant in Assiut university hospital, Egypt.

Hammad H, Mohamed I, El-Badawy O, Zakaria A, Shabaan L, Aly S Iran J Microbiol. 2023; 15(2):208-218.

PMID: 37193241 PMC: 10183067. DOI: 10.18502/ijm.v15i2.12471.

References

Liu P, Li X, Luo M, Xu X, Su K, Chen S . Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis. Microb Drug Resist. 2017; 24(2):190-198. PMC: 5873294. DOI: 10.1089/mdr.2017.0061. View

Agyeman A, Bergen P, Rao G, Nation R, Landersdorfer C . A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2019; 55(1):105833. DOI: 10.1016/j.ijantimicag.2019.10.014. View

Kohler P, Volling C, Green K, Uleryk E, Shah P, McGeer A . Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis. Infect Control Hosp Epidemiol. 2017; 38(11):1319-1328. DOI: 10.1017/ice.2017.197. View

Nassar M, Hazzah W, Bakr W . Evaluation of antibiotic susceptibility test results: how guilty a laboratory could be?. J Egypt Public Health Assoc. 2019; 94(1):4. PMC: 6329728. DOI: 10.1186/s42506-018-0006-1. View

Karlowsky J, Kazmierczak K, Young K, Motyl M, Sahm D . In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis. 2020; 96(4):114925. DOI: 10.1016/j.diagmicrobio.2019.114925. View

Trecarichi E, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G . Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016; 91(11):1076-1081. DOI: 10.1002/ajh.24489. View

Humphries R, Ambler J, Mitchell S, Castanheira M, Dingle T, Hindler J . CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. J Clin Microbiol. 2018; 56(4). PMC: 5869819. DOI: 10.1128/JCM.01934-17. View

Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E . Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing . Microb Drug Resist. 2019; 25(9):1357-1364. DOI: 10.1089/mdr.2018.0234. View

Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X . Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019; 38(12):2275-2281. DOI: 10.1007/s10096-019-03673-1. View

10.

Tian D, Pan F, Wang C, Sun Y, Zhang H . Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant among pediatric patients in Shanghai. Infect Drug Resist. 2018; 11:1935-1943. PMC: 6207262. DOI: 10.2147/IDR.S175584. View

11.

Matuschek E, Brown D, Kahlmeter G . Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect. 2013; 20(4):O255-66. DOI: 10.1111/1469-0691.12373. View

12.

del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D . Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect. 2005; 11(7):540-6. DOI: 10.1111/j.1469-0691.2005.01184.x. View

13.

Robilotti E, Deresinski S . Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Rep. 2014; 6:80. PMC: 4166937. DOI: 10.12703/P6-80. View

14.

Zheng X, Wang J, Xu W, Xu J, Hu J . Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant bloodstream infections in the intensive care unit. Antimicrob Resist Infect Control. 2017; 6:102. PMC: 5625719. DOI: 10.1186/s13756-017-0256-2. View

15.

Shu L, Lu Q, Sun R, Lin L, Sun Q, Hu J . Prevalence and phenotypic characterization of carbapenem-resistant strains recovered from sputum and fecal samples of ICU patients in Zhejiang Province, China. Infect Drug Resist. 2018; 12:11-18. PMC: 6302810. DOI: 10.2147/IDR.S175823. View

16.

Watkins R, Deresinski S . Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?. Expert Rev Anti Infect Ther. 2015; 13(4):405-7. DOI: 10.1586/14787210.2015.1018825. View

17.

Ji S, Lv F, Du X, Wei Z, Fu Y, Mu X . Cefepime combined with amoxicillin/clavulanic acid: a new choice for the KPC-producing K. pneumoniae infection. Int J Infect Dis. 2015; 38:108-14. DOI: 10.1016/j.ijid.2015.07.024. View

18.

Xu L, Sun X, Ma X . Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017; 16(1):18. PMC: 5371217. DOI: 10.1186/s12941-017-0191-3. View

19.

van Duin D, Kaye K, Neuner E, Bonomo R . Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75(2):115-20. PMC: 3947910. DOI: 10.1016/j.diagmicrobio.2012.11.009. View

20.

van Duin D, Cober E, Richter S, Perez F, Cline M, Kaye K . Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect. 2014; 20(12):O1117-20. PMC: 4265572. DOI: 10.1111/1469-0691.12714. View